Interfering substances are an important potential source of error in laboratory analyses that can be present in otherwise normal clinical specimens. While accuracy and precision are assessed routinely, interfering substances often are not suspected or recognized. Substances known to interfere with laboratory assays arise from endogenous (bilirubin, protein, lipids, hemoglobin) and exogenous (therapeutic and recreational drugs and their metabolites) sources. An awareness of potential interference can help reduce the risk of reporting erroneous laboratory values that could affect patient care adversely.
Contrast media are used commonly to enhance T 1 -weighted images in magnetic resonance (MR) imaging. Gadolinium (Gd), a lanthanide ion with 7 unpaired electrons and an especially long electronic relaxation time, is widely used as a contrast agent. 1 Because it is intrinsically toxic, in part by blocking calcium channels, Gd must be chelated with an appropriate ligand to allow clinical use. 2 These Gd complexes can be linear or macrocyclic. Gd contrast agents that are used clinically are known to be powerful chelators and have been reported to interfere with laboratory assays.
An early report described artifactual decreases in serum calcium measurements after the administration of gadodiamide. 3 This interference was noted when colorimetric methods of calcium analysis were used, such as o-cresolphthalein complexone (OCPC), methylthymol blue (MTB) and Arsenazo III methods but not with inductively coupled plasma-atomic emission spectroscopy or ion-selective electrode methods. These authors postulated that gadodiamide dissociates under the acidic conditions of the colorimetric assays, causing the chromophore to bind with the free ligand, thereby causing apparent decreases in measured calcium as fewer chromophore-calcium complexes were available for measurement. Negative interference by gadodiamide with OCPC and MTB serum calcium assays was confirmed. 4 These authors presented evidence that the cause of the interference was due to dissociation of Gd 3+ ions from their ligand and complexation with the chromophore used in the calcium assay. Recently, a large retrospective study showed spurious decreases in serum calcium concentrations in patients following gadodiamide administration. 5 In addition, these authors studied 3 other commonly used MR contrast agents, gadoversetamide, gadopentetate dimeglumine, and gadoteridol, and found that gadoversetamide interfered with a single OCPC calcium assay, but gadopentetate dimeglumine and gadoteridol did not. This study did not examine any other calcium methods.
Gd MR contrast agents have been reported to show interference with other analytes. Increases in serum iron and bilirubin concentrations were observed in healthy volunteers after gadopentetate dimeglumine administration and attributed to mild hemolysis during the venipuncture. 6 Published data also indicated that angiotensin-converting enzyme (ACE) activity could be inhibited by gadodiamide and gadopentetate dimeglumine due to a transmetallation effect. 7, 8 These authors observed in vivo and in vitro effects that were strongest with linear Gd complexes.
Despite these scattered reports, to the best of our knowledge, there are no detailed reports about the potential effects of various Gd contrast agents on common analytes measured in the clinical laboratory. At the University of Utah Hospital, Salt Lake City, it is estimated that more than 700 MR scans are done per month and that in more than half of these, patients receive Gd contrast agents to enhance imaging before the procedure. Hospital inpatients, in particular, are more likely to have blood work done after having received a Gd contrast agent and, therefore, might be most prone to have misleading laboratory results.
The goal of the present study was to assess potential analytic interference by 4 commonly used Gd contrast agents for multiple analytes and multiple analyzers. Experimentally, we focused on interference with analytic methods using serum samples supplemented with the agents in vitro. Because different institutions might encounter different combinations of contrast agents and analytic analytes, we attempted to evaluate multiple routine methods for selected methods that we thought might be the most subject to clinically significant interference, the divalent cations in particular. We hope that by increasing awareness about Gd interference and by providing a more complete list of affected analytes and specific methods of analysis that are free of interference, we can help reduce the number of potentially erroneous laboratory results generated.
Materials and Methods
Four commercially available Gd contrast agents were studied: gadodiamide (Omniscan, Amersham Health, Princeton, NJ); gadoversetamide, (Optimark, Mallinckrodt, St Louis, MO); gadopentetate dimeglumine (Magnevist, Berlex, Wayne, NJ); and gadoteridol (Prohance, Bracco, Princeton, NJ). All 4 agents have similar volumes of distributions, peak concentrations, dosing recommendations, and renal clearance.
The Gd concentration of each agent for intravenous administration is 0.5 mol/L. A 10-fold dilution with deionized water was performed to a Gd concentration of 50 mmol/L. Pooled human serum was supplemented with the 4 contrast agents to a final concentration of 0.5 mmol/L, corresponding to the estimated peak serum concentration achieved in vivo for each agent at a standard dose of 0.1 mmol/kg. From the initial 0.5-mmol/L concentrations, further dilutions were made with serum to Gd concentrations of 0.25, 0.125, and 0.0625 mmol/L to simulate the decreases seen in vivo as the agents are cleared from the body. All studies using samples from human subjects were approved by the institutional review board of the University of Utah Health Sciences Center, Salt Lake City.
Initially, 41 analytes were assayed in duplicate using a Modular P chemistry analyzer in samples containing 0.5-mmol/L concentrations of the 4 agents ❚Table 1❚. All reagents were used according to the manufacturer's instructions. Nonsupplemented serum served as a control. Six additional analytes were studied using other analyzers (Table 1) . Any analytes showing clinically significant differences in the presence of a contrast agent were rerun, using serial dilutions of the agent.
Calcium was studied further by using the AU 400 and Dimension RxL analyzers (Table 1) , both of which have an OCPC method of analysis. Two instruments that use Arsenazo III dye methods for calcium measurement, the AU 400 (both OCPC and Arsenazo III methods are available from Olympus) and Vitros 950, an ion-selective electrode method on the Synchron LX-20, and inductively coupled plasma mass spectrometry (ICP-MS) also were used (Table 1) . Ionized calcium was measured by using the Bayer model 865 blood gas analyzer (Table 1) .
Total iron binding capacity (TIBC) was studied with the Dimension RxL analyzer. Iron assays were performed on the Vitros 950 and Synchron LX-20 analyzers and by ICP-MS. The Dimension RxL and Vitros 950 iron and TIBC assays use ferene. The Modular P and Synchron LX-20 iron and TIBC assays use ferrozine. Magnesium was studied with the Dimension RxL, Modular P, Synchron LX-20, and Vitros 950 analyzers, which use MTB, xylidyl blue, calmagite, and formazan, respectively, and by ICP-MS. Zinc was assayed using a manual colorimetric kit (Table 1) and by ICP-MS. The percentage of recovery of the analyte in the presence of contrast agent was calculated by taking the average of supplemented serum run in duplicate, dividing by the average of the nonsupplemented serum run in duplicate, and multiplying by 100. No correction was made for dilution with the contrast agents because this introduced less than 1% error. Significant findings were defined as any interference greater than 2% for sodium, greater than 5% for calcium and chloride, and greater than 10% for all other analytes. The SEM was calculated for each data point for any analyte that exhibited a clinically significant effect.
Results
We studied the effects of all 4 MR contrast agents on all analytes listed in Table 1 . The results of clinically significant interference are summarized in ❚Table 2❚. Interference was found initially for 3 assays on the Modular P analyzer. When compared with control results, significant differences in recoveries were seen for ACE (26% and 32%), calcium (80% and 79%), and TIBC (127% and 129%) in serum supplemented with 0.5-mmol/L concentrations of gadodiamide and gadoversetamide, respectively. For these 3 analytes, serial dilutions of the contrast agents were made to examine the concentration dependence of the interference.
Results of these experiments for ACE are shown in ❚Figure 1❚, for calcium in ❚Figure 2❚, and for TIBC in ❚Figure 3❚.
Because gadodiamide-and gadoversetamide-supplemented samples showed significant interference with calcium measurements on the Modular P instrument, which uses the OCPC method of analysis, further investigation was performed with the AU 400 and Dimension RxL analyzers that both use an OCPC method. Calcium recoveries of 76% and 78% for the AU 400 and 91% and 91% for the Dimension RxL analyzers were observed with 0.5-mmol/L concentrations of gadodiamide and gadoversetamide, respectively. With increasing dilutions, this interference was shown to decrease in a near linear manner (Figure 2 ). Two analyzers that use Arsenazo III dye methods for calcium analysis (AU 400 and Vitros 950), an ionselective electrode method (Beckman Coulter Synchron LX-20), an ionized calcium method, and ICP-MS showed no interference with calcium measurements by any of the 4 agents.
In addition to the interference with TIBC measurements on the Modular P, interference was demonstrated on the Dimension RxL analyzer with recoveries of 149% for gadodiamide and 121% for gadoversetamide (0.5-mmol/L concentrations, Figure 3 ). Owing to the increases in TIBC observed, we studied iron recoveries, which had not shown a significant interference when assayed on the Modular P analyzer. Significant decreases were observed for the Synchron LX-20 (75% and 78%, at 0.5-mmol/L concentrations, Although magnesium measurements were not affected by any of the 4 agents on the Modular P analyzer, we studied magnesium measurements with additional analyzers because magnesium is a divalent cation with chemical properties similar to calcium. Magnesium recoveries were not affected by any of the 4 agents on the Dimension RxL or Vitros 950 analyzers. However, 0.5-mmol/L concentrations of gadodiamide and gadoversetamide led to increased magnesium recoveries on the Synchron LX-20 analyzer of 117% and 124%, respectively ❚Figure 5❚. No interference was shown for magnesium when quantified by ICP-MS.
Because ACE, a zinc-dependent metallopeptidase, initially showed interference on the Modular P, we measured zinc with a manual colorimetric assay in samples supplemented with a 0.5-mmol/L concentration of all 4 contrast agents. Significant interference was observed for all 4 agents with recoveries as follows: 15% for gadodiamide, 26% for gadoversetamide, 42% for gadopentetate dimeglumine, and 87% for gadoteridol ❚Figure 6❚. The interference was dose dependent but not linear. No interference was shown for zinc when measured by ICP-MS.
Total bilirubin showed borderline interference with 86% recovery for gadodiamide, gadoversetamide, and gadopentetate dimeglumine that we suspected might be secondary to the low bilirubin concentration (0.7 mg/dL [12.0 µmol/L]) present in the original serum pool. Therefore, the experiment was repeated on a serum pool with a total bilirubin concentration of 8.7 mg/dL (148.8 µmol/L). Supplementation with each of the 4 agents at a concentration of 0.5 mmol/L did not produce a clinically significant interference (recoveries, 105%-106%), suggesting the original findings might be due to poor assay precision at a low bilirubin concentration. No clinically significant interference was noted for any of the immunoassays evaluated on dedicated immunoassay analyzers that were evaluated.
Discussion
Our results show that Gd MR contrast agents can produce analytic interference, both positive and negative, with assays performed in the clinical laboratory, including ACE, calcium, iron, magnesium, TIBC, and zinc. Gadodiamide and gadoversetamide produced the most interference, although iron measured in samples supplemented with gadopentetate dimeglumine showed interference and a manual colorimetric zinc assay showed interference with gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadoteridol. All of the analytes affected are endogenous divalent cations or related to divalent cations in some manner. In some cases, the solid square for the data point is as large as or larger than the error bar. For product information, see the "Materials and Methods" section and Table 1 . In some cases, the solid square for the data point is as large as or larger than the error bar. For product information, see the "Materials and Methods" section and Table 1 . Because interference observed for calcium, iron, magnesium, and zinc was not seen with all methods tested, contamination of the contrast agents with any of these elements is unlikely. All analytes with which interference was found, except ACE, use chromophore dye methods of analysis. The Gd contrast agents can dissociate, and a complex can form between Gd 3+ ions and the assay chromophore, and/or a complex between divalent cations and the dissociated ligand can form. 4 Interference can occur when the Gd 3+ binds with the chromophore or the contrast agent ligand binds with the analyte being measured. For the former, the interference might be positive or negative, while for the latter, it would be expected to be negative. It is noteworthy that for the Vitros 950 iron method, gadodiamide and gadoversetamide produced clinically significant positive interference, while gadopentetate dimeglumine produced a clinically significant negative interference. The exact mechanism of this interference is unclear.
The ACE assay measures the rate of conversion of N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine to furylacryloylphenylalanine and glycylglycine spectrophotometrically under alkaline conditions. Because ACE depends on zinc for activity, it is likely that the dissociated contrast agent ligand binds zinc and reduces the rate of reaction, giving a falsely low ACE activity. Interference was observed for gadodiamide and gadoversetamide. No interference was seen with gadopentetate dimeglumine. This is in contrast with results from an earlier study that found inhibition of ACE by In some cases, the solid square for the data point is as large as or larger than the error bar. For product information, see the "Materials and Methods" section and Table 1 . In some cases, the solid square for the data point is as large as or larger than the error bar. For product information, see the "Materials and Methods" section and Table 1 .
gadopentetate dimeglumine that was comparable to that observed for gadodiamide. 5 One possible explanation is that the concentration of free ligand in gadopentetate dimeglumine preparations has been reduced from previous levels. Gadodiamide and gadoversetamide were the only 2 agents that showed interference with the calcium measurements. The AU 400, Dimension RxL, and Modular P instruments all use an OCPC method for calcium analysis. These assays operate under alkaline conditions, and it is possible that the Gd 3+ binds to the OCPC dye. Consequently, less chromophore is available to bind with calcium ions and a negative interference results. Our results for the Modular P calcium method are consistent with those in a recent report. 5 We did not find a clinically significant interference with the Arsenazo III methods of calcium analysis on the AU 400 and Vitros 950. It is interesting that these assays are performed under acidic conditions. A previous study that examined the Kodak Ektachem method (now Vitros) found a negative interference of greater than 5%, but this was with a gadodiamide concentration that was 3 times that used in our study. 3 We used serum supplemented with the peak concentration of each agent that would be achieved in vivo with a standard dose (0.1 mmol/kg). Higher concentrations can be achieved clinically, as in MR angiography, so that more analytes and methods could be affected and the magnitude of the effect could be greater than we observed.
In the iron assays, the Synchron LX-20 uses ferrozine as the chromophore dye; it is interesting that the Modular P also uses ferrozine, but no effect was seen on iron measurement with that platform. The Dimension RxL uses the ferene chromophore, and no interference was detected with this assay. All iron methods studied include a step to reduce ferric to ferrous iron, which then is available to bind with the chromophore. All iron assays studied occur under acidic test conditions, making dissociation of the Gd contrast agent unlikely. The Dimension RxL, Modular P, and Vitros 950 use ascorbic acid as a reducing agent, whereas the Synchron LX-20 uses hydroxylamine and thioglycolate. It is possible that these 2 compounds unique to this assay account for the negative interference seen in this assay. The Vitros 950 uses a sulfonamide chromophore that is different from the others and could cause the positive interference seen with the iron measurement on that assay; we are unsure why there was negative interference with gadopentetate dimeglumine in the same assay.
The only magnesium measurement method demonstrating interference was the Synchron LX-20, in which positive interference was seen with gadodiamide and gadoversetamide. All methods use a chromophore to bind with magnesium that then is measured by spectrophotometry. No effect was seen with the Dimension RxL, which uses MTB; the Modular P, which uses xylidyl blue; or the Vitros 950, which uses formazan dye. The Synchron LX-20 uses calmagite dye. This assay is performed under alkaline conditions, as is the xylidyl blue assay on the Modular P analyzer. Whereas the Dimension RxL, Modular P, and Vitros 950 all include compounds to chelate calcium that potentially might interfere with the assay, no calcium chelator is mentioned in the Synchron LX-20 package insert. Perhaps the alkaline conditions of the Synchron LX-20 assay could promote association between Gd 3+ and the chromophore, creating a colored complex resembling a magnesium-chromophore complex and causing a positive interference. In some cases, the solid square for the data point is as large as or larger than the error bar. For product information, see the "Materials and Methods" section and Table 1 .
Positive interference was seen with TIBC on the Dimension RxL and Modular P analyzers with gadodiamide and gadoversetamide, while both agents produced negative interference for the iron assay on the Synchron LX-20 and positive interference in the Vitros 950 iron assay. It is interesting that gadopentetate dimeglumine produced negative interference in the Vitros 950 iron assay. Previously, increases in serum iron and bilirubin concentrations observed after administration of gadopentetate dimeglumine were attributed to slight hemolysis during venipuncture. 6 The positive interference we observed for iron was not secondary to RBC breakdown because it occurs in the absence of RBCs. We also did not observe increased bilirubin values, as was reported by the same authors. Both TIBC assays use chromophores that bind to ferrous iron. In the first step of both assays, free MR contrast agent ligand could bind some excess added ferrous iron under alkaline conditions, causing less iron to be available to bind to the unsaturated transferrin sites. This then could result in a higher unbound iron binding capacity measurement and an elevation in TIBC as seen here.
While no interference was seen with the ICP-MS method of zinc analysis, negative interference was seen with all 4 contrast agents on a manual colorimetric assay. The kit used for these measurements used formazan dye and an alkaline buffer. Binding of the formazan dye by the Gd 3+ under alkaline conditions could account for this negative interference. The greatest amount of interference was observed with gadodiamide and gadoversetamide. The large error bars on Figure  6 result from the manual nature of this assay. Of all the affected analytes, calcium is the most likely to produce a result that leads to unnecessary treatment. 5 This could adversely affect patient care. If the calcium concentration must be measured before elimination is complete, we recommend administering an agent other than gadodiamide or gadoversetamide, using a non-OCPC method or measuring ionized calcium. It is noteworthy that the effect of calcium has been documented to occur after in vivo administration of a contrast agent. 3 It also is important to recognize potential interference with other analytes. One limitation of our data for additional analytes is that it was all generated in vitro. Further verification of our findings should be conducted using data from patients or research subjects from whom serum samples are obtained before and after administration of the contrast agent. The possibility exists after in vivo administration of a contrast agent that the formation of metabolites could alter an agent's interference profile.
Based on our in vitro data, additional warnings of the interference described herein seem to be necessary for Gd contrast agents and in vitro diagnostic assays. Currently, the package inserts for gadodiamide and gadoversetamide state that these products interfere with calcium measurements by some colorimetric assays. The Modular P calcium assay package insert includes Gd agents as potential causes of interference and mentions gadodiamide specifically but does not mention gadoversetamide.
Based on these findings, we recommend using care when interpreting results of the analyte-method combinations listed in Table 2 for patients who recently have received Gd contrast agents, particularly gadodiamide and gadoversetamide. It is estimated that with normal renal function, the elimination half-life of the agents is approximately 90 minutes. The package insert for gadodiamide recommends waiting 12 to 24 hours between contrast agent administration and blood specimen collection to ensure that the contrast agent has been cleared. A longer waiting period might be necessary for patients with renal insufficiency. The average half-life of gadodiamide in patients with severely reduced renal function is 34 hours. 9 
